{
}
Poseida has reached an agreement with Roche for a $1.5 billion acquisition, following a series of negotiations that began with Roche's initial disinterest in 2023. The deal includes $9 per share in cash and up to $4 per share tied to milestone achievements, establishing Roche's capability in off-the-shelf cell therapies. This acquisition builds on a partnership that started in 2022, which has evolved through various proposals and collaborations over the years.
Ottimo Pharma has launched under the leadership of former Seagen CEO David Epstein, focusing on a bi-functional antibody, jankistomig, that targets both PD-1 and VEGFR2 to enhance cancer immunotherapy. The startup aims to initiate its first clinical trial next year, with backing from Medicxi. Epstein emphasizes the drug's potential to significantly benefit patients with various solid tumors, while industry veterans Mehdi Shahidi and James Sabry join the team to drive development and strategy.
James Sabry
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
roche acquires poseida for 1.5 billion after extensive negotiations and proposals
United States Dollar
Hoffmann-La Roche AG
Astellas Pharma Inc.
CHE
USA
JPN
Mark Gergen
James Sabry
Show more
18:30 10.12.2024
oncology startup ottimo pharma emerges with innovative dual-pathway cancer drug
Seagen Inc.
Pfizer Inc.
Hoffmann-La Roche AG
BioNTech SE
Bristol-Myers Squibb Company
Merck & Co., Inc.
Mehdi Shahidi
James Sabry
David Epstein
Show more
11:52 28.10.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Economic Indicators
Global Trade Developments
Market Analysis and Predictions
Countries:
Companies:
Currencies:
People: